'Kill' the messenger: Targeting of cell-derived microparticles in lupus nephritis

Autoimmunity Reviews

Volumn 15, Issue 7, 2016, Pages 719-725

  Nielsen, Christoffer T ^a   Rasmussen, Niclas S ^a   Heegaard, Niels H H ^b,c   Jacobsen, Søren ^a  

^a Rigshospitalet   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Apoptosis; Electron dense deposits; Galectin 3 binding protein; Immune complexes; Lupus nephritis; Microparticles

Indexed keywords

AUTOANTIGEN; GALECTIN 3 BINDING PROTEIN; IMMUNOGLOBULIN; INTEGRIN; MEMBRANE PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; CELL DEATH; ELETRON DENSE DEPOSIT; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANE MICROPARTICLE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; APOPTOSIS; COMPLICATION; IMMUNOLOGY; KIDNEY; PATHOLOGY;

ANTIGEN-ANTIBODY COMPLEX; APOPTOSIS; CELL-DERIVED MICROPARTICLES; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

EID: 84961262350     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.03.009     Document Type: Review

References (91)

1. Jacobsen S., Petersen J., Ullman S., Junker P., Voss A., Rasmussen J.M., et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. Clin Rheumatol 1998, 17(6):468-477.
2. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358(9):929-939.
3. Hanly J.G., O'Keeffe A.G., Su L., Urowitz M.B., Romero-Diaz J., Gordon C., et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2015.
4. Faurschou M., Dreyer L., Kamper A.L., Starklint H., Jacobsen S. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken) 2010, 62(6):873-880.
5. Jacobsen S., Petersen J., Ullman S., Junker P., Voss A., Rasmussen J.M., et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998, 17(6):478-484.
6. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20(5):1103-1112.
7. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353(21):2219-2228.
8. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., Garrido Ed E.R., Danieli M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46(8):2121-2131.
9. Hahn B.H., McMahon M.A., Wilkinson A., Wallace W.D., Daikh D.I., Fitzgerald J.D., et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012, 64(6):797-808.
10. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon G.E., Danieli M.G., et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69(1):61-64.
11. Wofsy D., Hillson J.L., Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012, 64(11):3660-3665.
12. Dooley M.A., Jayne D., Ginzler E.M., Isenberg D., Olsen N.J., Wofsy D., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365(20):1886-1895.
13. Houssiau F.A., D'Cruz D., Sangle S., Remy P., Vasconcelos C., Petrovic R., et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010, 69(12):2083-2089.
14. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., Martinez-Berriotxoa A., Egurbide M.V., Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11(4):R109.
15. Borchers A.T., Leibushor N., Naguwa S.M., Cheema G.S., Shoenfeld Y., Gershwin M.E. Lupus nephritis: a critical review. Autoimmun Rev 2012, 12(2):174-194.
16. Lech M., Anders H.J. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013, 24(9):1357-1366.
17. Kalaaji M., Mortensen E., Jorgensen L., Olsen R., Rekvig O.P. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006, 168(6):1779-1792.
18. Fenton K. The effect of cell death in the initiation of lupus nephritis. Clin Exp Immunol 2015, 179(1):11-16.
19. Weening J.J., D'Agati V.D., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15(2):241-250.
20. van Bavel C.C., Fenton K.A., Rekvig O.P., der Vlag J van, JH Berden Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2008, 58(7):1892-1899.
21. Mjelle J.E., Rekvig O.P., der Vlag J van, KA Fenton Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 2011, 44(5):373-383.
22. Faurschou M., Penkowa M., Andersen C.B., Starklint H., Jacobsen S. Renal cell apoptosis in human lupus nephritis: a histological study. Lupus 2009, 18(11):994-999.
23. Pisetsky D.S. Microparticles as autoantigens: making immune complexes big. Arthritis Rheum 2012, 64(4):958-961.
24. Obermoser G., Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010, 19(9):1012-1019.
25. Nielsen C.T. Circulating microparticles in systemic lupus erythematosus. Dan Med J 2012, 59(11):B4548.
26. Pisetsky D.S., Lipsky P.E. Microparticles as autoadjuvants in the pathogenesis of SLE. Nat Rev Rheumatol 2010, 6(6):368-372.
27. Munoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6(5):280-289.
28. Radic M., Marion T.N. Neutrophil extracellular chromatin traps connect innate immune response to autoimmunity. Semin Immunopathol 2013, 35(4):465-480.
29. Cline A.M., Radic M.Z. Apoptosis, subcellular particles, and autoimmunity. Clin Immunol 2004, 112(2):175-182.
30. Colonna L., Lood C., Elkon K.B. Beyond apoptosis in lupus. Curr Opin Rheumatol 2014, 26(5):459-466.
31. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999, 5(6):694-697.
32. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998, 19(1):56-59.
33. Herrmann M., Voll R.E., Zoller O.M., Hagenhofer M., Ponner B.B., Kalden J.R. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41(7):1241-1250.
34. Ravichandran K.S., Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 2007, 7(12):964-974.
35. Schiller M., Bekeredjian-Ding I., Heyder P., Blank N., Ho A.D., Lorenz H.M. Autoantigens are translocated into small apoptotic bodies during early stages of apoptosis. Cell Death Differ 2008, 15(1):183-191.
36. Munoz L.E., Janko C., Grossmayer G.E., Frey B., Voll R.E., Kern P., et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009, 60(6):1733-1742.
37. Rosen A., Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999, 6(1):6-12.
38. Dieker J., Muller S. Post-translational modifications, subcellular relocation and release in apoptotic microparticles: apoptosis turns nuclear proteins into autoantigens. Folia Histochem Cytobiol 2009, 47(3):343-348.
39. Utz P.J., Hottelet M., Schur P.H., Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997, 185(5):843-854.
40. Casciola-Rosen L.A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179(4):1317-1330.
41. Kruse K., Janko C., Urbonaviciute V., Mierke C.T., Winkler T.H., Voll R.E., et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010, 15(9):1098-1113.
42. Radic M., Marion T., Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004, 172(11):6692-6700.
43. Zirngibl M., Furnrohr B.G., Janko C., Munoz L.E., Voll R.E., Gregory C.D., et al. Loading of nuclear autoantigens prototypically recognized by systemic lupus erythematosus sera into late apoptotic vesicles requires intact microtubules and myosin light chain kinase activity. Clin Exp Immunol 2015, 179(1):39-49.
44. Lane J.D., Allan V.J., Woodman P.G. Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells. J Cell Sci 2005, 118(Pt 17):4059-4071.
45. Bilyy R.O., Shkandina T., Tomin A., Munoz L.E., Franz S., Antonyuk V., et al. Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J Biol Chem 2012, 287(1):496-503.
46. Ullal A.J., Marion T.N., Pisetsky D.S. The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells. Clin Immunol 2014, 154(2):178-187.
47. Cline A.M., Radic M.Z. Murine lupus autoantibodies identify distinct subsets of apoptotic bodies. Autoimmunity 2004, 37(2):85-93.
48. Mevorach D., Zhou J.L., Song X., Elkon K.B. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998, 188(2):387-392.
49. Coleman M.L., Sahai E.A., Yeo M., Bosch M., Dewar A., Olson M.F. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001, 3(4):339-345.
50. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011, 85(21):10945-10954.
51. Liu C.L., Tangsombatvisit S., Rosenberg J.M., Mandelbaum G., Gillespie E.C., Gozani O.P., et al. Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther 2012, 14(1):R25.
52. Pieterse E., Hofstra J., Berden J., Herrmann M., Dieker J., der Vlag J van Acetylated histones contribute to the immunostimulatory potential of eutrophil extracellular traps in systemic lupus erythematosus. Clin Exp Immunol 2015, 179(1):68-74.
53. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3(73).
54. Hakkim A., Furnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010, 107(21):9813-9818.
55. Leffler J., Ciacma K., Gullstrand B., Bengtsson A.A., Martin M., Blom A.M. A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res Ther 2015, 17:205.
56. Leffler J., Martin M., Gullstrand B., Tyden H., Lood C., Truedsson L., et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012, 188(7):3522-3531.
57. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3(73).
58. Campbell A.M., Kashgarian M., Shlomchik M.J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med 2012, 4(157).
59. Knight J.S., Subramanian V., O'Dell A.A., Yalavarthi S., Zhao W., Smith C.K., et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis 2014.
60. Lood C., Blanco L.P., Purmalek M.M., Carmona-Rivera C., De Ravin S.S., Smith C.K., et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med 2016.
61. Piccin A., Murphy W.G., Smith O.P. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007, 21(3):157-171.
62. Yuana Y., Bertina R.M., Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011, 105(3):396-408.
63. Gyorgy B., Modos K., Pallinger E., Paloczi K., Pasztoi M., Misjak P., et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes due to shared biophysical parameters. Blood 2010.
64. Yanez-Mo M., Siljander P.R., Andreu Z., Zavec A.B., Borras F.E., Buzas E.I., et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 2015, 4:27066.
65. Nielsen C.T., Ostergaard O., Stener L., Iversen L.V., Truedsson L., Gullstrand B., et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 2012, 64(4):1227-1236.
66. Ullal A.J., Reich C.F., Clowse M., Criscione-Schreiber L.G., Tochacek M., Monestier M., et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun 2011.
67. Ostergaard O., Nielsen C.T., Iversen L.V., Tanassi J.T., Knudsen S., Jacobsen S., et al. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum 2013, 65(10):2680-2690.
68. Nielsen C.T., Ostergaard O., Rekvig O.P., Sturfelt G., Jacobsen S., Heegaard N.H. Galectin-3 binding protein links circulating microparticles with electron dense glomerular deposits in lupus nephritis. Lupus 2015.
69. Beer A., Andre S., Kaltner H., Lensch M., Franz S., Sarter K., et al. Human galectins as sensors for apoptosis/necrosis-associated surface changes of granulocytes and lymphocytes. Cytometry A 2008, 73(2):139-147.
70. Cloutier N., Tan S., Boudreau L.H., Cramb C., Subbaiah R., Lahey L., et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med 2013, 5(2):235-249.
71. Boilard E., Nigrovic P.A., Larabee K., Watts G.F., Coblyn J.S., Weinblatt M.E., et al. Platelets amplify inflammation in arthritis via Collagen-dependent microparticle production. Science 2010, 327(5965):580-583.
72. Biro E., Nieuwland R., Tak P.P., Pronk L.M., Schaap M.C., Sturk A., et al. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007, 66(8):1085-1092.
73. Nauta A.J., Trouw L.A., Daha M.R., Tijsma O., Nieuwland R., Schwaeble W.J., et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002, 32(6):1726-1736.
74. Schiller M., Parcina M., Heyder P., Foermer S., Ostrop J., Leo A., et al. Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. J Immunol 2012, 189(4):1747-1756.
75. Dieker J., Tel J., Pieterse E., Thielen A., Rother N., Bakker M., et al. Circulating apoptotic microparticles in SLE patients drive the activation of DC subsets and prime neutrophils for NETosis. Arthritis Rheumatol 2015.
76. Nielsen C.H., Rasmussen J.M., Voss A., Junker P., Leslie R.G. Diminished ability of erythrocytes from patients with systemic lupus erythematosus to limit opsonized immune complex deposition on leukocytes and activation of granulocytes. Arthritis Rheum 1998, 41(4):613-622.
77. Toong C., Adelstein S., Phan T.G. Clearing the complexity: immune complexes and their treatment in lupus nephritis. Int J Nephrol Renov Dis 2011, 4:17-28.
78. Nisihara R.M., Magrini F., Mocelin V., Messias-Reason I.J. Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum Immunol 2013, 74(8):907-910.
79. Sjowall C., Olin A.I., Skogh T., Wettero J., Morgelin M., Nived O., et al. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis. Autoimmunity 2013, 46(3):205-214.
80. Hohenester E., Sasaki T., Timpl R. Crystal structure of a scavenger receptor cysteine-rich domain sheds light on an ancient superfamily. Nat Struct Biol 1999, 6(3):228-232.
81. Inohara H., Akahani S., Koths K., Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996, 56(19):4530-4534.
82. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100(5):2610-2615.
83. Nielsen C.T., Lood C., Ostergaard O., Iversen L.V., Voss A., Bengtsson A., et al. Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus. Lupus Sci Med 2014, 1(1).
84. Sasaki T., Brakebusch C., Engel J., Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 1998, 17(6):1606-1613.
85. Kang E.H., Moon K.C., Lee E.Y., Lee Y.J., Lee E.B., Ahn C., et al. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 2009, 18(1):22-28.
86. Thijssen V.L., Hulsmans S., Griffioen A.W. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008, 172(2):545-553.
87. Tinari N., Kuwabara I., Huflejt M.E., Shen P.F., Iacobelli S., Liu F.T. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001, 91(2):167-172.
88. Macanovic M., Sinicropi D., Shak S., Baughman S., Thiru S., Lachmann P.J. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996, 106(2):243-252.
89. Davis J.C., Manzi S., Yarboro C., Rairie J., Mcinnes I., Averthelyi D., et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 1999, 8(1):68-76.
90. Kronbichler A., Brezina B., Quintana L.F., Jayne D.R. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 2016, 15(1):38-49.
91. Linkermann A., Green D.R. Necroptosis. N Engl J Med 2014, 370(5):455-465.